Related Experiment Videos
Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer
M Markman1, A Kennedy, K Webster
1Cleveland Clinic Taussig Cancer Center and the Department of Gynecology/Obstetrics and Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. markmam@cesmtp.ccf.org
Abstract:
It has long been recognized that individuals with ovarian cancer who initially respond to a platinum-containing chemotherapeutic regimen may exhibt a second response to platinum (cisplatin or carboplatin) at the time of recurrence. In this report, we describe three individuals with metastatic endometrial cancer who demonstrated secondary responses to platinum/paclitaxel-based regimens. Endometrial cancer should be added to the list of malignancies for which platinum and/or paclitaxel are considered as second-line treatment options in patients previously responding to the agents.